

MASS GENERAL BRIGHAM

INVESTIGATOR CHECKLIST

for

Transfer of Tissue/Data to Academic Institutions/Collaborators

Is Mass General Brigham Innovation Review Needed?

IF the answer to ANY of these 4 questions is YES, then your transfer requires either a:

Materials Transfer Agreement (MTA) formally negotiated on your behalf by Mass General Brigham Innovation (formerly Research Ventures and Licensing); or

Data Transfer Agreement (DTA formally negotiated by either Mass General Brigham Innovation or the Mass General Brigham Clinical Trials Office (CTO) (see data/tissue transfer grid)

1. Will you be receiving compensation of any kind that has a value in excess of what it will cost to prepare, collect and ship the Specimens/Patient Data? (“Compensation” includes monetary or other compensation, and includes a subcontract to your laboratory or research group.)
2. Was the Specimen/Patient Data collected during a research protocol or clinical study that was funded by a company, or that was part of a collaboration or any other agreement with a company? **NOTE: If this transfer of specimens/data is covered under a Clinical Trials Agreement negotiated by the Mass General Brigham Clinical Trials Office (CTO), an MTA is not required.**
3. Is the recipient scientist planning to use the Specimens/Patient Data in connection with research supported by a for-profit company (if you don't know you will need to find out from the collaborator)?
4. Have these Specimens/Patient Data previously been transferred to a for-profit company?

It is the investigator’s responsibility to contact Mass General Brigham Innovation directly to begin the process of negotiating the transfer agreements. Contact information is provided below.

<http://innovation.partners.org/>